Results 31 to 40 of about 68,171 (350)

Review of medication-assisted treatment for opioid use disorder

Journal of Osteopathic Medicine, 2022
Abstract Context The American opioid epidemic has necessitated the search for safe and effective means of treatment for opioid use disorder (OUD). Medication-assisted treatment (MAT) encompasses select medications that are proven effective treatments for OUD.
Nessreen, Ghanem, Devin, Dromgoole, Ahmad, Hussein, Richard T, Jermyn   +3 more
openaire   +2 more sources

Medicaid expansion and treatment for opioid use disorders in Oregon: an interrupted time-series analysis

Addiction Science & Clinical Practice, 2019
Background The study examined the association of the Affordable Care Act’s 2014 Medicaid expansion on the use of psychosocial services and pharmacotherapies for opioid use disorders among Oregon Medicaid recipients.
Dennis McCarty, Yifan Gu, John W. McIlveen, Bonnie K. Lind   +3 more
doaj   +1 more source

Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program

Substance Abuse Treatment, Prevention, and Policy, 2023
Background Medication for opioid use disorder (MOUD) is the gold standard treatment for opioid use disorder. Traditionally, “success” in MOUD treatment is measured in terms of program retention, adherence to MOUD, and abstinence from opioid and other ...
Megan K. Reed, Kelsey R. Smith, Francesca Ciocco, Richard W. Hass, Avery Lin Cox, Erin L. Kelly, Lara C. Weinstein   +6 more
doaj   +1 more source

Health disparities in chronic liver disease

Hepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian, Marina Serper, Norah Terrault, Lauren D. Nephew   +3 more
wiley   +1 more source

Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods [PDF]

, 2017
Opioid use disorder is a highly disabling psychiatric disorder, and is associated with both significant functional disruption and risk for negative health outcomes such as infectious disease and fatal overdose. Even among those who receive evidence-based
Barlow, David H., Fitzmaurice, Garrett M., Greenfield, Shelly F., McHugh, R. Kathryn, Votaw, Victoria R., Weiss, Roger D.   +5 more
core   +1 more source

The association of criminal justice supervision setting with overdose mortality: a longitudinal cohort study. [PDF]

, 2020
Background and aimsDespite the high prevalence of substance use among people in the US criminal justice system, little is known about the incidence of overdose mortality by use patterns, drug convictions and supervision setting.
Anderson R. N., Aos S., Bronson J., Center for Substance Abuse Treatment, Kaeble D., Kaeble D., Michigan Judicial Institute, National Center for Health Statistics, Zeng Z.   +8 more
core   +2 more sources

Addressing opioid use disorder among rural pregnant and postpartum women: a study protocol

Addiction Science & Clinical Practice, 2020
Background Opioid use disorder (OUD) among women delivering at a hospital has increased 400% from 1999–2014 in the United States. From the years 2007 to 2016, opioid-related mortality during pregnancy increased over 200%, and drug-overdose deaths made up
M. Aryana Bryan, Marcela C. Smid, Melissa Cheng, Katherine T. Fortenberry, Amy Kenney, Bhanu Muniyappa, Danielle Pendergrass, Adam J. Gordon, Gerald Cochran   +8 more
doaj   +1 more source

Navigating intersecting public health crises: a qualitative study of people with opioid use disorders' experiences during the COVID-19 pandemic

Substance Abuse Treatment, Prevention, and Policy, 2022
Background The decades-long opioid epidemic and the more recent COVID-19 pandemic are two interacting events with significant public health impacts for people with opioid use disorder (OUD).
Dennis P. Watson, Monte D. Staton, Christine E. Grella, Christy K. Scott, Michael L. Dennis   +4 more
doaj   +1 more source

Clinical effectiveness and treatment satisfaction between two triple‐therapy regimens in treating neuropathic pain: A real‐world data

Ibrain, EarlyView., 2023
This study compared the clinical effectiveness and treatment satisfaction of Pregabalin and Gabapentin triple therapy for neuropathic pain in a real‐world setting. The primary outcome measured the reduction in mean Self‐Administered Leeds Assessment of Neuropathic Symptoms and Signs pain score value from baseline to 12 weeks posttreatment.
Nithya Raju, Samyuktha Villavan, Saranya Ravi, Roja Murugesan, Panneerselvam Theivendren, Vennila Jaganathan, Redlin Jani Rajan, Krupanidhi Karunanithi   +7 more
wiley   +1 more source

Patient reported goals for medications for opioid use disorder: A theory of proximal goal attainment

Exploratory Research in Clinical and Social Pharmacy, 2023
Background: There exist substantial patient barriers to accessing medications for opioid use disorder (MOUD), including travel distance, stigma, and availability of MOUD providers.
Kenneth C. Hohmeier, Alina Cernasev, Christina Leibold, Todd M. Moore, Erica Schlesinger, Ileana Arce, Wesley Geminn, Marie Chisholm-Burns, Gerald Cochran   +8 more
doaj   +1 more source